MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/annonc/mdu443

Медицинская библиотека · Annals of oncology : official journal of the European Society for Medical Oncology · 2014

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Abramson J S, Feldman T, Kroll-Desrosiers A R, Muffly L S, Winer E, Flowers C R, Lansigan F, Nabhan C, Nastoupil L J, Nath R, Goy A, Castillo J J, Jagadeesh D, Woda B, Rosen S T, Smith S M, Evens A M

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear.

PATIENTS AND

METHODS

We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using univariate and multivariate analyses.

RESULTS

PTCL subtypes included PTCL, not otherwise specified (PTCL-NOS) (31%), anaplastic large T-cell lymphoma (ALCL) (26%), angioimmunoblastic T-cell lymphoma (23%), NK/T-cell lymphoma (7%), acute T-cell leukemia/lymphoma (6%), and other (7%). Median age was 62 years (range 18-95 years), and 74% had stage III-IV disease. Twenty-three (7%) patients received only palliative care whereas 318 received chemotherapy: CHOP-like regimens (70%), hyperCVAD/MA (6%), or other (18%). Thirty-three patients (10%) underwent stem-cell transplantation (SCT) in first remission. The overall response rate was 73% (61% complete); 24% had primary refractory disease. With 39-month median follow-up, 3-year progression-free survival (PFS) and overall survival (OS) were 32% and 52%. PFS and OS for PTCL patients were significantly inferior to matched patients with DLBCL. On multivariate analysis, stage I-II disease was the only significant pretreatment prognostic factor [PFS: hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.34-0.85, P = 0.007; OS: HR 0.42, 95% CI 0.22-0.78, P = 0.006]. ALK positivity in ALCL was prognostic on univariate analysis, but lost significance on multivariate analysis. The most dominant prognostic factor was response to initial therapy (complete response versus other), including adjustment for stage and SCT [PFS: HR 0.19, 95% CI 0.14-0.28, P < 0.0001; OS: HR 0.26, 95% CI 0.17-0.40, P < 0.0001]. No overall survival difference was observed based on choice of upfront regimen or SCT in first remission.

CONCLUSIONS

This analysis identifies early-stage disease and initial treatment response as dominant prognostic factors in PTCL. No clear benefit was observed for patients undergoing consolidative SCT. Novel therapeutic approaches for PTCL are critically needed.

Для цитирования: Abramson J S, Feldman T, Kroll-Desrosiers A R, Muffly L S, Winer E, Flowers C R, Lansigan F, Nabhan C, Nastoupil L J, Nath R, Goy A, Castillo J J, Jagadeesh D, Woda B, Rosen S T, Smith S M, Evens A M. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.. Annals of oncology : official journal of the European Society for Medical Oncology. 2014. DOI: 10.1093/annonc/mdu443.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.